Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904794 | 1.00 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL1542636 | 1.00 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL796349 | 0.89 | DGAT1 (0.40) | DGAT1ALDH1A1HPGD | |
| SCHEMBL77788 | 0.89 | DGAT1 (0.40) | DGAT1ALDH1A1HPGD | |
| SCHEMBL77789 | 0.89 | DGAT1 (0.40) | DGAT1ALDH1A1HPGD | |
| SCHEMBL25292338 | 0.82 | ELANE (0.32) | DGAT1 | |
| SCHEMBL19406048 | 0.81 | CYP2D6 (0.30) | — | |
| SCHEMBL15843648 | 0.80 | DGAT1 (0.44) | DGAT1ALDH1A1HPGD | |
| SCHEMBL15843647 | 0.80 | DGAT1 (0.44) | DGAT1ALDH1A1HPGD | |
| SCHEMBL20278337 | 0.80 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 868 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | claimed |
| CN-116891459-A | Synthesis method of polysubstituted triazinane compound | 湖北九康通生物医药有限公司 | 2023-10-17 | — | — | CN | claimed |
| WO-2023193818-A1 | METHOD FOR SYNTHESIZING POLYSUBSTITUTED TRIAZINE COMPOUND | 湖北九康通生物医药有限公司 | 2023-10-12 | — | — | WO | claimed |
| CN-107573360-B | A kind of preparation method of multiple target point small molecule compound S63845 | 都创(上海)医药科技有限公司 | 2019-08-09 | — | — | CN | claimed |
| CN-109942474-A | A kind of neighbour's nitrine-hydrazine class compound and preparation method thereof | 华中科技大学 | 2019-06-28 | — | — | CN | claimed |
| CN-109890790-A | A kind of preparation method of Oseltamivir and its isomers | 广东东阳光药业有限公司 | 2019-06-14 | — | — | CN | claimed |
| CN-109761951-A | A kind of liquid-crystal compounds and its synthetic method of the structure containing dioxanes | 江苏和成新材料有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-106854208-B | The synthetic method of tumor inhibitor MLN4924 | 成都柏睿泰生物科技有限公司 | 2019-04-09 | — | — | CN | claimed |
| CN-109265327-A | A kind of khapra beetle sex pheromone and preparation method thereof | 西北农林科技大学 | 2019-01-25 | — | — | CN | claimed |
| CN-106866876-B | A kind of embedding medium, embedding method and the application of smooth transparence biological tissue | 华中科技大学 | 2018-12-07 | — | — | CN | claimed |
| CN-102958931-A | Process for the synthesis of carbonucleoside and intermediates for use therein | ALPHORA RES INC | 2013-03-06 | — | — | CN | claimed |
| CN-101555266-B | Preparation method of Tibifuding | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2011-11-30 | — | — | CN | claimed |
| CN-102212095-A | Preparation methods of capecitabine and intermediate thereof | SHANGHAI INST PHARM INDUSTRY | 2011-10-12 | — | — | CN | claimed |
| CN-101142181-B | Process for the preparation of enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN LA ROCHE | 2011-05-04 | — | — | CN | claimed |
| CN-100582095-C | Chiral inversion methods for (S)-(+)-and (R)-(-)-10, 11-dihydro-10-hydroxy-5H-dibenzo/b, f/aza-5-carboxamides and optically enriched mixtures thereof | PORTELA & CA SA | 2010-01-20 | — | — | CN | claimed |
| CN-101555266-A | Preparation method of Tibifuding | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-10-14 | — | — | CN | claimed |
| CN-101472877-A | Preparation of chirally pure amino alcohol intermediates, derivatives thereof and uses thereof | WYETH CORP (US) | 2009-07-01 | — | — | CN | claimed |
| CN-101142181-A | Process for the preparation of enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | CN | claimed |
| CN-101048396-A | Process for the preparation of citalopram and escitalopram | ADORKEM TECHNOLOGY SPA (IT) | 2007-10-03 | — | — | CN | claimed |
| CN-101023061-A | Method for chiral inversion of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof | PORTELA & CA SA (PT) | 2007-08-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | PFAS, ENPP1, NAAA | DGAT1 629/4885ALDH1A1 2704/4885HPGD 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.